Death Clock CEO's Three Hard Lessons From a 'Slow Failure' Startup

Brent Franson spent four years building Most Days, a mental-health app that attracted real users but could never acquire them cheaply enough to sustain a viable business. The insidious part, he says, wasn't that the product was obviously bad — it was that it was just good enough to keep rationalizing another round of changes. He calls this pattern 'slow failure': a startup that lingers because its leaders keep convincing themselves it might soon work, rather than facing the hard truth that the unit economics are broken.

In late 2024, Franson made a clean break — shutting down Most Days entirely and discarding the entire codebase his San Francisco team had spent years building. No rebrand, no pivoting the same product, no salvaging the tech. The team then went all-in on Death Clock, an AI-driven consumer-health platform where users input data like cholesterol levels, diet, and sleep habits, and receive an estimated lifespan alongside personalized longevity recommendations. Franson, 44, describes it as an 'AI private doctor.'

The name itself became a deliberate strategic weapon. The team had floated 'More Years' as a safer alternative, but ultimately kept their provocative internal working title. When Franson went back to Most Days' investors — offering them either a partial return or a bet on the new venture — reactions to the name split sharply. Nobody forgot it, which was exactly the point. In a consumer-health market where well-funded incumbents can outspend startups on customer acquisition, Death Clock's name functions as free distribution — a built-in conversation starter that cuts through the noise.

Franson, who previously sold a software company to WeWork in 2019, distills his hardest-won insight into a single maxim: first-time founders obsess over product quality; second-time founders obsess over distribution. Most Days had product. It lacked a way to reach customers without burning cash. Death Clock is, in part, an experiment in whether a name alone can serve as a marketing engine. Franson acknowledges the risk — that the shock-value branding could undermine credibility as a serious health product. The company is also deliberately leaving money on the table by refusing to sell peptides, a trendy longevity product its clinical advisors don't believe the science supports.